Last reviewed · How we verify

NCT00953719

36 mm Ceramic-on-Ceramic Acetabular Cup Total Hip Replacement

Completed NA Results posted Last updated 10 April 2019
What this trial tests

NA trial testing 36 mm ceramic head on a ceramic acetabular liner in Non-inflammatory Degenerative Joint Disease in 243 participants. Completed in 1 July 2013.

Timeline
1 April 2003
Primary endpoint
1 August 2008
1 July 2013

Quick facts

Lead sponsorDePuy Orthopaedics
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment243
Start date1 April 2003
Primary completion1 August 2008
Estimated completion1 July 2013
Sites5 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

DePuy Orthopaedics — full company profile →

Who can join

Adults 20 to 75, any sex, with Non-inflammatory Degenerative Joint Disease. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Total Harris Hip Score Primary · At final follow-up visit, 24 months or later, up to 72 months

The Harris Hip scoring system assigns a numeric value to responses from patients and assessments made by a surgeon. A score of 91-100 is excellent, 81-90 is good, 71-80 is fair, 70 or below is poor. The patient records the following: pain level, need for assistance when walking, presence of a limp, distance able to walk, ability to put on shoes and socks, climb stairs, use public transportation and the length of time one is able to comfortably sit in a chair are all scored. The Total Harris Hip Score is a sum of its subscores (Pain, Function, Activities, Deformity, and Range of Motion).

GroupValue95% CI
36 mm Ceramic-on-ceramic95.6± 8.8
28 mm Ceramic-on-polyethylene94.9± 8.9
Harris Hip Subscale Score: Pain Secondary · At final follow-up visit, 24 months or later, up to 72 months

The Harris Hip's pain subscale is a numeric value from 0 to 44. A lower score indicates more pain; a score of 44 indicates no pain.

GroupValue95% CI
36 mm Ceramic-on-ceramic41.4± 6.3
28 mm Ceramic-on-polyethylene41.1± 5.7
Harris Hip Subscale Score: Function Secondary · At final follow-up visit, 24 months or later, up to 72 months

The Harris Hip's function subscale is a numeric value from 0 to 33. A lower score indicates less function; a score of 33 indicates no limitations in function level.

GroupValue95% CI
36 mm Ceramic-on-ceramic32.1± 2.5
28 mm Ceramic-on-polyethylene31.6± 4.0
Harris Hip Subscale Score: Activities Secondary · At final follow-up visit, 24 months or later, up to 72 months

The Harris Hip's Activities subscale is a numeric value from 0 to 14. A lower score indicates a lower ability to perform daily activities; a score of 14 indicates no limitations in daily activities.

GroupValue95% CI
36 mm Ceramic-on-ceramic13.2± 1.4
28 mm Ceramic-on-polyethylene13.0± 1.7
Harris Hip Subscale Score: Deformity Secondary · At final follow-up visit, 24 months or later, up to 72 months

The Harris Hip's Deformity subscale is a numeric value from 0 to 4. A lower score indicates more deformity; a score of 4 indicates no deformity.

GroupValue95% CI
36 mm Ceramic-on-ceramic4.0± 0
28 mm Ceramic-on-polyethylene4.0± 0
Harris Hip Subscale Score: Range of Motion Secondary · At final follow-up visit, 24 months or later, up to 72 months

The Harris Hip's Range of Motion subscale is a numeric value from 0 to 5. A lower score indicates a lower range of motion; a score of 5 indicates full range of motion.

GroupValue95% CI
36 mm Ceramic-on-ceramic4.9± 0.1
28 mm Ceramic-on-polyethylene4.9± 0.2
Harris Hip Score Longitudinal Analysis Secondary · 6 week, 6 month, 12 month, 24 month, 36 month, and 48 months post-operatively

The Harris Hip scoring system assigns a numeric value to responses from patients and assessments made by a surgeon, with a range of 0 to 100. Lower scores indicate a worse outcome and a score of 100 is the best possible outcome. Longitudinal analysis (repeated measures) was performed to compare post-operative Harris Hip sores over time.

6 week Total Harris Hip Score
GroupValue95% CI
36 mm Ceramic-on-ceramic52.6± 10.9
28 mm Ceramic-on-polyethylene52.0± 9.5
6 month Total Harris Hip Score
GroupValue95% CI
36 mm Ceramic-on-ceramic93.1± 10.0
28 mm Ceramic-on-polyethylene93.4± 9.7
12 month Total Harris Hip Score
GroupValue95% CI
36 mm Ceramic-on-ceramic95.5± 6.5
28 mm Ceramic-on-polyethylene95.2± 7.6
24 month Total Harris Hip Score
GroupValue95% CI
36 mm Ceramic-on-ceramic95.7± 8.2
28 mm Ceramic-on-polyethylene93.7± 10.2
36 month Total Harris Hip Score
GroupValue95% CI
36 mm Ceramic-on-ceramic96.6± 6.8
28 mm Ceramic-on-polyethylene97.0± 4.6
48 month Total Harris Hip Score
GroupValue95% CI
36 mm Ceramic-on-ceramic94.6± 10.1
28 mm Ceramic-on-polyethylene93.5± 11.1
Proportion of Composite Successes Secondary · At final follow-up visit, 24 months or later, up to 72 months

A subject was deemed to be a composite success at 24 months or greater if at the time of last clinical follow-up there had not been a revision of any THA components, the latest Harris Hip score was 80 or greater, and on the latest radiographic evaluation there were no radiolucencies greater than 2mm, no evidence of acetabular migration greater than 4mm, no change in acetabular shell inclination angle greater than 4 degrees, and no osteolysis.

GroupValue95% CI
36 mm Ceramic-on-ceramic90.5
28 mm Ceramic-on-polyethylene90.1

Adverse events — posted to ClinicalTrials.gov

Time frame: Intra-operatively through last follow-up, which was up to 72 months post-op for some subjects.. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

36 mm Ceramic-on-ceramic
Serious: 0/169 (0%)
Deaths:
28 mm Ceramic-on-polyethylene
Serious: 0/74 (0%)
Deaths:
Other adverse events (50 terms — click to expand)

ReactionSystem36 mm Ceramic-on-ceramic28 mm Ceramic-on-polyethyl…
Postoperative Systemic: MusculoskeletalMusculoskeletal and connective tissue disorders
Postoperative Operative Site: Trochanteric BursitisMusculoskeletal and connective tissue disorders
Postoperative Operative Site: MusculoskeletalMusculoskeletal and connective tissue disorders
Postoperative Systemic: CardiovascularCardiac disorders
Postoperative Systemic: GenitourinaryRenal and urinary disorders
Postoperative Systemic: DermatologicalSkin and subcutaneous tissue disorders
Postoperative Systemic: GastrointestinalGastrointestinal disorders
Postoperative Operative Site: Other - SqueakingMusculoskeletal and connective tissue disorders
Postoperative Operative Site: PainGeneral disorders
Postoperative Systemic: HEENTEar and labyrinth disorders
Postoperative Operative Site: Other - ClickingMusculoskeletal and connective tissue disorders
Postoperative Systemic: Central Nervous SystemNervous system disorders
Postoperative Systemic: Endocrine/MetabolicEndocrine disorders
Postoperative Operative Site: Iliopsoas TendinitisMusculoskeletal and connective tissue disorders
Postoperative Operative Site: Pain - ThighMusculoskeletal and connective tissue disorders
Postoperative Operative Site: Wound ProblemInjury, poisoning and procedural complications
Postoperative Systemic: Other - FellInjury, poisoning and procedural complications
Postoperative Systemic: Thrombosis/ThrombophlebitisVascular disorders
Postoperatve Systemic: CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)
Postoperative Systemic: HematologicalBlood and lymphatic system disorders
Postoperative Systemic: Peripheral Nervous SystemNervous system disorders
Postoperative Systemic: Respiratory SystemRespiratory, thoracic and mediastinal disorders
Postoperative Operative Site: DislocationInjury, poisoning and procedural complications
Postoperative Operative Site: Muscle WeaknessMusculoskeletal and connective tissue disorders
Postoperative Systemic: NeurologicalNervous system disorders
Postoperative Operative Site: DermatologicalSkin and subcutaneous tissue disorders
Postoperative Operative Site: Heterotopic Bone FormationInjury, poisoning and procedural complications
Postoperative Operative Site: Other - FellInjury, poisoning and procedural complications
Intraoperative: CardiovascularCardiac disorders
Postoperative Operative Site: Deep InfectionInfections and infestations
Postoperative Operative Site: Other - Hip PainInjury, poisoning and procedural complications
Intra-operative: 2cm non-displaced fracture of posterior femoral neckInjury, poisoning and procedural complications
Intraoperative: Blemish on Ceramic ComponentGeneral disorders
Intraoperative: Broken Drill BitGeneral disorders
Intraoperative: HematologicalBlood and lymphatic system disorders
Intraoperative: Liner Fracture During SurgeryGeneral disorders
Postoperative Systemic: Other - Insect BiteInjury, poisoning and procedural complications
Postoperative Systemic: Pregnancy - 7 Months GestationPregnancy, puerperium and perinatal conditions
Postoperative Systemic: Wound ProblemInjury, poisoning and procedural complications
Postoperative Operative Site: Acetabular Component FailureGeneral disorders

Data from ClinicalTrials.gov NCT00953719 adverse events section.

Sponsor's own description

This study is a supplement to the 28 mm Ceramic-on-Ceramic study which was designed to evaluate artificial hips with a 28 mm ceramic head and liner to determine whether they perform as well as artificial hips with a 28 mm ceramic head and a polyethylene liner. This arm of the study is designed to compare a 36 mm ceramic head and sleeve with a subset of the control (28mm ceramic head and a polyethylene sleeve) from the original study (G030075) (NCT#00208507) with additional follow-up, to determine if they perform as well.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Non-inflammatory Degenerative Joint Disease

Currently open trials in the same condition.

Other DePuy Orthopaedics trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00953719.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing